Therapeutic nuclear medicine leverages radionuclides for targeted cancer treatment, facing challenges in delivery, safety, and regulatory compliance.
Human Body Imaging
Radiopharmaceuticals can be divided into radioactive molecules or radionuclides that facilitate diagnostic imaging and radiotherapy. All commercially produced radiopharmaceuticals must be approved by the US Food and Drug Administration (FDA) before use in the clinical setting.
Also, radiopharmaceuticals must possess various characteristics to be desirable for nuclear medicine applications. The radionuclide decay should be able to produce gamma emissions of suitable energy for diagnostic imaging. The ideal energy for a gamma camera is 100-200 keV compared to 511 keV for positron emission tomography imaging.
Radiopharmaceuticals should not contain particle radiation such as beta emissions which can contribute to the patient radiation doses, even though beta emissions have therapeutic properties.
Furthermore, radionuclides should have an effective half-life for clinical applications. Moreover, the radionuclide should be carrier-free and not contaminated with a stable radionuclide. This is because it can harm biodistribution and labelling efficiency if the specific activity changes.
Considering all the above, one of the best radionuclides for radiopharmaceuticals is technetium-99m, especially for gamma camera imaging. Also, the radiopharmaceutical should rapidly localise in a specific part of the body according to the intended application. In addition to this, background clearance should be rapid to achieve reasonable target-to-background ratios.
Radiotherapy treatments involving the radionuclide attached to a vector (antibody) to deliver radioactivity to specific cells are called radioimmunotherapy.
For example, the radiopharmaceutical iodine-131 tositumomab, yttrium-90 ibritumomab and yttrium-90 epratuzumab are used to treat Non-Hodgkin’s lymphoma.
Also, samarium-153 (Quadramet) is effective in relieving the pain of bone cancer and prostate and breast cancer. The most used radioisotope for treating bone metastasis in the US is samarium-153 EDTMP (lexidronam).
The pure beta emitter yttrium-90 is used to relieve the pain of arthritis in larger synovial joints. Other radiopharmaceuticals include Iofetamine (I-123 iodoamphetamine), used for non-invasive evaluation of local cerebral blood flow in cerebrovascular accidents, and dysprosium used as an aggregated hydroxide for synovectomy (removal of synovial tissue surrounding a joint ) treatment of arthritis.
You Are Here: Home » radiopharmaceuticalsTherapeutic nuclear medicine leverages radionuclides for targeted cancer treatment, facing challenges in delivery, safety, and regulatory compliance.
PET imaging dramatically enhances early disease detection, significantly improving patient outcomes in various medical fields.
Thorium-227 emerges in nuclear medicine, revolutionizing cancer treatment through precise, effective radiotheranostic and therapeutic applications.
FAPI revolutionises oncology with precise Gallium-68 diagnostics and targeted Lutetium-177 therapy for cancer.
Somatostatin Receptor Targeting Agents offer groundbreaking diagnostic and therapeutic solutions for neuroendocrine tumour management and care.
225Ac-MTI-201, targeting MC1R, offers groundbreaking, targeted treatment for uveal melanoma with minimal side effects.
Actinium-225 is a rare, promising isotope revolutionizing targeted alpha therapy for various resistant cancers.
225Ac-FPI-2068 and 111In-FPI-2107 represent a major advancement in targeted alpha therapy for various solid tumours.
225Ac-FPI-1434 advances in clinical trials, targeting IGF-1R in chemo-resistant solid tumors with promising results.
225Ac-DOTAZOL enhances 177Lu-radiotherapy in bone diseases, particularly effective in prostate cancer, as shown in preclinical studies.
225Ac-DOTATOC advances GEP-NET treatment, offering targeted, effective therapy for patients resistant to traditional methods.
225Ac-DOTA-YS5 targets CD46 in prostate cancer, promising precision and effectiveness in therapy.
225Ac-DOTA-SP, a breakthrough in targeted alpha therapy, offers precise cancer treatment with minimal side effects, revolutionising oncological approaches.
Radiopharmaceuticals, combining radioactive and pharmaceutical elements, enable precise diagnosis and treatment in nuclear medicine.
Zirconium radiopharmaceuticals enhance nuclear medicine with precise diagnostics and potential therapeutic applications.
Lutetium radiopharmaceuticals significantly advance targeted cancer treatment and diagnostic capabilities.
Lead radiopharmaceuticals herald a transformative era in cancer treatment with promising, targeted therapeutic approaches.
Gallium, predicted by Mendeleev, now revolutionises medical diagnostics with its unique radiopharmaceutical applications in oncology.
In Brazil, the growing radiopharmaceutical market, driven by chronic disease and advanced imaging technologies, is becoming increasingly significant in healthcare.
Technetium-99m, discovered in 1937, transformed medical imaging with its versatile and safe diagnostic applications.
Copper radiopharmaceuticals offer groundbreaking diagnostic and therapeutic applications, revolutionising nuclear medicine, particularly in oncology and cardiology.
From Becquerel's discovery in 1896 to modern medical applications, radionuclides have revolutionised our approach to science, medicine, and industry.
[F-18]NAV-4694 shows promise in Alzheimer's detection, with a strong safety profile and clear regulatory pathways.
Alzheimer's disease stems from genetic mutations and lifestyle factors, leading to brain plaque accumulation and dementia.
Immuno-PET merges monoclonal antibodies with PET imaging, transforming precision oncology through enhanced tumor detection and monitoring.
Cyclotrons advance nuclear medicine by efficiently producing key radionuclides for diagnostics and treatment within hospital settings.
Zevalin, combining monoclonal antibodies and radiation, offers hope against refractory B-cell non-Hodgkin's lymphoma with targeted therapy.
Yttrium-90 chloride is pivotal in radioimmunotherapy, targeting cancer cells precisely while minimizing damage to surrounding tissues.
Xenon-133 is pivotal for imaging lungs and assessing brain flow, enhancing diagnoses in modern medicine.
Thallium-201 chloride is pivotal in myocardial perfusion imaging, diagnosing ischemic heart disease, and assessing myocardial viability.
Technetium-99m sulfur colloid provides critical diagnostics for liver, spleen, and bone marrow using targeted nuclear imaging.
Technetium-99m UltraTag RBCs enhance blood pool imaging and precisely localize gastrointestinal bleeding in non-invasive diagnostic procedures.
Technetium-99m medronate is vital in nuclear medicine for precise bone imaging and detecting osteogenesis abnormalities.
Technetium-99m Mebrofenin is pivotal for hepatobiliary imaging, assessing liver function, gallbladder diseases, and biliary obstructions.
Strontium-89 chloride: a potent palliative for metastatic bone cancer-induced pain, through calcium-mimicking, localized beta radiation, ensuring effective, safer pain relief.
The Molybdenum-99 Generator crucially produces Technetium-99m for medical imaging, through radioactive decay, aiding numerous diagnostic procedures globally.
Positrons, alpha particles, beta particles, and electron capture contribute to nuclear medicine, diagnostics, and diverse scientific applications.
Lutetium-177 Dotatate selectively binds to SSTRs on NET cells, delivering targeted radiation, minimizing collateral damage, and reducing side effects.
Iodine-131 sodium iodide, a radioactive isotope, is used in diagnosing and treating thyroid disorders and specific cancer therapies.
Iodine-131 Iobenguane (I-131 MIBG), a radiopharmaceutical agent, enables early diagnosis and targeted treatment of neuroendocrine tumours, improving patient outcomes.
Iodine-131 human serum albumin offers versatile diagnostic and therapeutic applications, despite limitations like radiation exposure and a short half-life.
Indium-111 pentetreotide excels in detecting and localising neuroendocrine tumors, monitoring treatment, and identifying therapy candidates.
Fluorine-18 Fluoroestradiol PET imaging enables early breast cancer detection, accurate staging, and treatment response monitoring, improving patient outcomes.
Iodine-125 iothalamate, with high albumin affinity, ensures accurate GFR measurement, minimal radiation exposure, stability, and cost-effectiveness in diagnostics.
Iodine-125 Human Serum Albumin effectively measures blood volume, assesses vascular permeability, and evaluates protein-losing gastroenteropathy for accurate diagnosis.
Iodine-123 Sodium Iodide capsules aid in diagnosing thyroid disorders, providing vital insights into thyroid function and structure.
Iodine-123 Ioflupane known as DaTscan aids in diagnosing Parkinson's disease by visualising dopamine transporters using SPECT imaging.
Iodine-123 iobenguane is vital for detecting, staging, and monitoring neuroendocrine tumours, guiding treatment, and offering prognostic insights.
Indium-111 Pentetate enables tumour detection, infection, inflammation tracking, and cerebrospinal fluid leak identification.
Indium-111 oxyquinoline enables diverse cellular imaging, crucial for detecting infections, thrombosis, tumours, and advancing stem cell research.
Indium-111 chloride effectively aids infection and inflammation imaging by labelling WBCs, enabling precise issue localisation and severity assessment.
Gallium-68 Gozetotide enhances PET imaging for oncology, targeting somatostatin receptors, and offering improved tumour detection and patient care.
Gallium-68 DOTATOC revolutionises neuroendocrine tumor diagnosis, enhancing PET imaging accuracy, sensitivity, and management in the medical field.
Alzheimer's disease, an age-related neurodegenerative disorder, impacts brain structure and function, requiring advanced imaging techniques for improved understanding and diagnosis.
Gallium-68 DOTATATE, a radiopharmaceutical, targets somatostatin receptors, aiding neuroendocrine tumor detection through PET imaging, enhancing diagnostic accuracy and patient outcomes.
Gallium-67 citrate is a radiopharmaceutical used for imaging infections, inflammation, cancer, and fever of unknown origin.
Fluorine-18 Flutemetamol, a radioactive tracer, for early detection of Alzheimer's disease through PET imaging, enhancing diagnostic accuracy.
Fluorine-18 Fludeoxyglucose, a radiotracer used in PET scans, enables precise cancer diagnosis, evaluating metabolic activity, and monitoring treatment efficacy non-invasively.
Fluorine-18 Flucicovine (Axumin) improves prostate cancer detection, enabling accurate diagnosis and targeted treatments with PET imaging.
Fluorine-18 Florbetapir, radiotracer, amyloid plaques, Alzheimer's disease, PET imaging, early diagnosis, pharmaceutical research, neurodegenerative disorders, brain.
Fluorine-18 Florbetaben is a radiotracer used in medical imaging to detect amyloid plaques in the brain.
Copper-64 DOTATE, a diagnostic radiopharmaceutical, effectively targets neuroendocrine tumours, enabling precise imaging and personalised treatment plans for cancer patients.
Carbon-14 urea, utilised in breath tests, effectively detects Helicobacter pylori infections, aiding gastric ulcer diagnosis and management.
Carbon-14 Choline, a radioactive isotope, improves medical imaging accuracy and expands molecular research, aiding cancer diagnosis and treatment.
SPECT imaging provides valuable functional information, aiding clinicians in diagnosing, planning treatments, and monitoring progress.
Theranostics is a cutting-edge approach that integrates diagnosis and therapy, enabling personalised and precise disease management.
Imaging agents can be used to evaluate organ function, detect cancer, measure blood flow and follow metabolic processes.
Radiopharmaceuticals are used in nuclear medicine for the application of medical imaging and therapy.
Radiopharmaceuticals enhance PET and SPECT imaging, enabling precise visualisation of physiological processes.
Application of aptamers in drug delivery systems and radiopharmacy.
A method uses polylactic acid as the polymer to encapsulate nano-hydroxyapatite.
Automated radiosynthesis of fluorine-18 choline using a modified TracerLab module.